Fiche publication
Date publication
décembre 2018
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DAGUINDAU Etienne
Tous les auteurs :
De Vos J, Baudoux E, Bay JO, Calmels B, Cras A, El Cheikh J, Guerout-Verite MA, Lacassagne MN, Lamure S, Letellier C, Menard AL, Daguindau E, Poiré X, Yakoub-Agha I, Guillaume T
Lien Pubmed
Résumé
Donor lymphocyte infusion (DLI) can be proposed to treat or prevent the relapse of malignant hemopathies following allogeneic stem cell transplantation. The efficiency has been mainly reported in the treatment of CML and low-grade lymphomas while the anti-tumoral activity is less in forms of acute leukemia and myelodysplastic syndromes. The GVL benefit should always be compared to the possible toxic effects of GVHD. This article updates the initial SFGM-TC recommendations, proposed in 2013, that were focused on the use of DLI. Doses of DLI in the context of haplo-identical stem cell transplantation are now indicated. We confirm that remaining mobilized stem cells may be used as classical DLI. The definition and the place of preemptive and prophylactic DLI are precisely given. Recommendations regarding the quality of thawed DLI as well as necessary clinical and biological follow-up are also described in detail.
Mots clés
Allogeneic stem cell transplantation, Allogreffe de cellules souches hématopoïétiques, Cellular immunotherapy, Donor lymphocyte infusion, Immunothérapie cellulaire, Injection de lymphocytes du donneur
Référence
Bull Cancer. 2018 Dec 20;:
